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SILENT CEREBRAL INFARCTION IN PATIENTS WITH NONRHEUMATIC 
ATRIAL FIBRILLATION. Mark L. Meyer and Michael D. Ezekowitz, Section 
of Cardiology, Department of Internal Medicine, Yale University School of 
Medicine, New Haven, Connecticut, and Kenneth E. James, Department of 
Veterans Affairs Cooperative Studies Program Coordinating Center, Palo 
Alto, California. 
Silent cerebral infarction has recently emerged as an entity found in 
subgroups of patients with a history of symptomatic stroke, TIA, carotid 
disease, or atrial fibrillation. To examine more closely the prevalence of 
silent cerebral infarction among patients with atrial fibrillation, data from 
cerebral CT scans from the Stroke Prevention in Nonrheumatic Atrial 
Fibrillation (SPINAF) study were analyzed. During the SPINAF study, which 
evaluated warfarin for the prevention of stroke in patients with 
nonrheumatic atrial fibrillation and no clinical evidence of previous stroke, 
non-contrast CT scans of the head were performed on all patients at entry, at 
the time of any neurologic event, and at termination of follow-up for those 
who completed the study without an event. These scans were evaluated by a 
central committee of six neurologists and neuroradiologists, and the location, 
size, and vascular territory of all lucent lesions were archived. We then 
determined the following: The prevalence of silent infarction in patients 
with atrial fibrillation, risk factors associated with silent infarction, the effect 
of warfarin therapy on the development of silent infarction, and the 
relationship between silent infarction and the development of symptomatic 
stroke. 

Of 516 evaluable scans, 77 (14.9 percent) had evidence of silent cerebral 
infarction. A univariate comparison found age (p=0.011), a history of 
hypertension (p=0.003), active angina (p=0.012), and mean systolic blood 
pressure (p<0.0001) to be independently predictive of silent infarction. The 
incidence rates of silent infarction were 1.77 and 0.77 percent per year for the 
warfarin and placebo treatment groups, respectively. Silent infarction was 
found to be suggestive of the development of symptomatic stroke (p=0.051), 
while warfarin did not appear to influence the development of silent 
infarction. 
We conclude that the prevalence of silent cerebral infarction among 
neurologically normal patients with atrial fibrillation was 14.9 percent, and 
that age, a history of hypertension, active angina, and mean systolic blood 
pressure were predictive of silent infarction. In addition, silent cerebral 
infarction was a marker of increased risk for the development of symptomatic 
stroke. Finally, we suggest a new mechanism for silent infarction, namely 





A. Cerebrovascular Disease 
1. Magnitude of the Problem and Definition 
Cerebrovascular disease is the third leading cause of death in 
developed countries, preceded only by heart disease and cancer. Its overall 
prevalence has been estimated at 794 per 100,000 population, with more than 
five percent of the population over 65 years of age affected. In the United 
States, current estimates indicate that in excess of 400,000 patients per year are 
discharged from hospitals following a stroke. The economic burden created 
by the hospitalization and subsequent treatment of stroke victims is one of 
the most onerous in health care today. 1 
A stroke is defined as an acute neurologic injury resulting from one of 
a number of pathologic processes. Clinically, strokes may vary in severity 
along a spectrum spanning silent strokes, detected only on neuroradiologic 
examination, and transient ischemic attacks (TIAs) which refer to any sudden 
focal neurologic deficit which resolves within 24 hours, to catastrophic events 
resulting in severe incapacitation or even sudden death. These clinical 
manifestations result from the interruption of the continuous supply of 
oxygenated blood which ensures normal brain function. Indeed animal 
experiments reveal that total cessation of blood flow results in irreversible 
cerebral infarction within three minutes. 1 
The categories of stroke may be broadly characterized as ischemic and 
hemorrhagic, with ischemic strokes being the more common. The risk 
factors for both categories include cardiac disease, previous stroke, age, and 
hypertension. It has been acknowledged that hypertension is the strongest 
risk factor for stroke, and thus the advent of antihypertensive therapy has 
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been the principal factor accounting for the dramatic decline of stroke-related 
mortality since 1975. Nevertheless, there are numerous other factors 
associated with cerebrovascular disease whose prominence continues to be 
uncovered by ongoing studies of the pathogenesis and prevention of stroke. 
2. .Etiology 
The causes of ischemic cerebrovascular disease (the category with 
which is the subject of this inquiry) may be divided into non-cardiac and 
cardiac factors (Tables 1 and 2). Among the important non-cardiac causes are 
atherosclerosis, arteritis, hematologic disorders, cerebral vasospasm, and 
reversible cerebral vasoconstriction. Additionally, certain conditions show 
associations of varying significance with ischemic cerebrovascular disease, 
including hypercoagulable states secondary to systemic disease, carcinoma, 
eclampsia, use of oral contraceptives, and lupus. 1 
The cardiac causes of ischemic cerebrovascular disease are multifold. 
However, these multiple etiologies share the common mechanism of 
systemic embolization (Table 2).3 One documented source of emboli arises as 
a result of the "paradoxical complications" of cardiac manipulation, including 
both cardiac catheterization and cardiac surgery. Emboli from the heart lodge 
in the middle cerebral artery or one of its branches 80 percent of the time, in 
the posterior cerebral artery or its branches 11 percent of the time, with the 
remainder finding their way to the vertebral or basilar arteries. 1 As indicated 
in Table 2, the left ventricle is an important source of systemic embolization, 
resulting from transmural myocardial infarction (anterior or inferior), left 
ventricular aneurysm, cardiomyopathy (left ventricular dysfunction), and less 
commonly, ventricular tumors. Cardiac valvulopathy is another important 
source of systemic emboli, resulting from endocarditis (infective and 
noninfective), prosthetic valve dysfunction, and rheumatic heart disease. 
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Additionally, stenosis and insufficiency of both the mitral and aortic valves, 
as well as mitral valve prolapse, contribute to the pathologic armamentarium 
of systemic emboli.3 
The most important source of systemic emboli is thrombus in the left 
atrium. Less commonly, atrial tumors (myxomas) and atrial septal 
aneurysms may cause strokes. Most commonly, left atrial thrombi occur as a 
consequence of atrial fibrillation, a condition resulting from multiple causes, 
listed in Table 3.3 Of note, while other sources of emboli in patients with 
atrial fibrillation have been postulated,^ it is widely assumed that the left 
atrium is the source of emboli in most of these patients.3 
B. Atrial Fibrillation as a Cause of Stroke 
1. Significance of the Arrhythmia 
The importance of atrial fibrillation as a source of systemic emboli 
must not be underestimated. To begin with, the incidence of atrial fibrillation 
in patients over 60 years of age without valvular disease is estimated to be 2-4 
percent per year.3 The prevalence of atrial fibrillation increases with age; 
indeed, the prevalence in patients greater than seventy years of age is 
estimated to be as high as nine percent.3 Furthermore, patients with 
nonvalvular atrial fibrillation have a five-fold excess of stroke relative to 
comparable patients in sinus rhythm,!'6-8 corresponding to a yearly incidence 
of approximately 5 percent.6 It has been shown that up to 35 percent of all 
patients with nonvalvular atrial fibrillation eventually suffer cerebral 
infarction.6 In addition, in a study of the four main cardiovascular 
conditions predisposing to stroke (hypertension, coronary heart disease, 
cardiac failure, and atrial fibrillation), the attributable risk of atrial fibrillation 
increased significantly with age (from 1.5 percent in the 50-59 age group, to 
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23.5 percent in the 80-89 age group), while the other conditions were either 
unaffected by or decreased in significance with age.2 Importantly, atrial 
fibrillation exerts a significant impact on the risk of stroke which is 
independent of associated cardiac abnormalities (hypertension, cardiac failure, 
coronary heart disease), although it has also been shown to increase the stroke 
risk in the overt presence of these conditions.2 A recent study of 154 
consecutive anterior circulation stroke patients with atrial fibrillation who 
were evaluated for alternative mechanisms of the stroke with carotid 
angiography or noninvasive cardiac testing found atrial fibrillation to be the 
sole stroke mechanism in 76 percent of these patients.^ 
Given the significant impact of atrial fibrillation on stroke, five recent 
clinical trials have evaluated the use of aspirin and or warfarin to prevent 
stroke in patients with atrial fibrillation.6-7,10-12 institution of preventative 
measures as soon as atrial fibrillation is diagnosed is important for two 
reasons. First, embolic events often occur shortly after atrial fibrillation first 
develops. One study reported that 33 percent of emboli occurred within one 
month and 66 percent within twelve months after its onset.3 And second, in 
many cases, the initial stroke causes severe disability. 1 What follows is a brief 
summary of the results of the five atrial fibrillation studies. 
2. Clinical Trials Evaluating Warfarin and Aspirin as a Means of 
Stroke Prevention^ 
The five atrial fibrillation trials were the Atrial Fibrillation, Aspirin, 
Anticoagulation Study from Copenhagen (AFASAK),10 the Stroke 
Prevention in Atrial Fibrillation Study (SPAF),6/13 the Boston Area 
Anticoagulation Trial for Atrial Fibrillation (BAATAF),H the Canadian 
Atrial Fibrillation Anticoagulation Study (CAFA),-7 and the Stroke 
Prevention in Nonrheumatic Atrial Fibrillation Study (SPINAF).!^ Each trial 
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evaluated the efficacy of warfarin, generally with the goal of a low 
prothrombin-time ratio (1.2-1.5). In addition, the AFASAK and SPAF trials 
evaluated aspirin as an alternative therapy (using 75 and 325 mg once per day, 
respectively). CAFA and SPINAF excluded aspirin and nonsteroidal anti¬ 
inflammatory agents, while the BAATAF study allowed the patients in the 
placebo group to use aspirin (325 mg once per day). All five studies were 
placebo-controlled, randomized studies which were terminated early. The 
BAATAF and AFASAK studies were not blinded, the SPAF study was double- 
blinded for aspirin but unblinded for warfarin, while the SPINAF and CAFA 
trials were double-blinded for warfarin. Each trial used stroke or a variant 
thereof as its primary endpoint. Finally, in the SPINAF and AFASAK 
studies, intermittent atrial fibrillation was an exclusion. 
The main result of all five trials was the demonstration of the efficacy 
of warfarin in protecting against systemic embolization, both in chronic (all 
five) and intermittent (CAFA, SPAF, BAATAF) atrial fibrillation. In the 
three unblinded studies (CAFA, SPAF, BAATAF), reduction in cerebral 
vascular events ranged from 67 to 86 percent. The double-blinded SPINAF 
trial had a 79 percent risk reduction of cerebral infarction, while the CAFA 
study, though terminated early, revealed a non-statistically significant trend 
in favor of warfarin. In addition, the SPINAF study indicated that warfarin 
protection may apply to recurrent cerebral infarction, as well as to the 
prevention of initial events. The risk of major hemorrhage secondary to low- 
intensity anticoagulation was similar for warfarin and placebo.7,10-11,13 The 
SPINAF study demonstrated a higher incidence of minor hemorrhage in the 
warfarin group. 
The benefit of aspirin remains controversial. The AFASAK study 
revealed no benefit of aspirin versus placebo, while the SPAF trial noted a 

6 
benefit of aspirin only in patients less than 75 years of age. In the SPAF 
population overall, however, the incidence of ischemic stroke and systemic 
embolization for aspirin-treated patients was 3.6 percent per year, versus 0.9 
percent per year for cerebral infarction alone in the warfarin-treated SPINAF 
patients. A recent "treatment-received" analysis of the BAATAF study found 
no support for the efficacy of aspirin in preventing stroke in patients with 
atrial fibrillation.14 This study revealed the unadjusted rate of stroke among 
patients in the aspirin group to be 3.9 percent, which was approximately 9 
times the rate among patients taking warfarin. And even after controlling for 
the imbalance resulting from the non-randomization of patients within the 
aspirin group with respect to coexisting risk factors, this study still 
demonstrated a 7-fold increase in stroke among the aspirin versus warfarin 
patients. 
Finally, despite these five trials, the subgroups of atrial fibrillation 
patients at high risk for stroke prevention remain somewhat elusive. The 
BAATAF study identified age as a positive risk factor, and both the BAATAF 
and SPINAF studies found active angina to positively influence the risk of 
stroke. There was controversy among the studies regarding the effect of 
mitral annular calcification, recent history of cardiac failure, left atrial size, 
decreased left ventricular function, and recent onset of arrhythmia.H/13 One 
group identified by all five trials to be at relatively low risk for embolic events 
includes those patients with "lone atrial fibrillation," defined as atrial 
fibrillation without concomitant structural heart disease, hypertension, or 
diabetes. This group constitutes approximately 2 to 4 percent of the 
population with chronic atrial fibrillation, and their risk of embolization is 
estimated at 1.3-1.4 percent per year.3 
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The overall recommendation which emerges from these five trials is 
for low-intensity anticoagulation with warfarin in all patients with non- 
valvular atrial fibrillation who can tolerate this therapy, with the exception of 
the subgroup of lone atrial fibrillators who do not require anticoagulation, but 
who may benefit from aspirin.3 As discussed above, the value of aspirin as a 
preventative measure is not resolved, but clearly any such benefit is 
substantially less than that afforded by therapeutic anticoagulation. Finally, 
the optimal dose for warfarin is the maintenance of a prothrombin-time ratio 
of 1.2 to 1.5, corresponding to an International Normalized Ratio (INR) of 1.38 
to 2.5;3/12-13 however, the lowest effective dose of warfarin has yet to be 
defined. If aspirin is to be used, the appropriate dose is thought to be 325 mg 
once per day.3 
C. Silent Cerebral Infarction 
1. Definition 
The preceding discussion of atrial fibrillation and stroke focused on 
prevention of clinically apparent events. However, as discussed earlier, 
strokes may vary in their severity from clinically silent to catastrophically 
incapacitating. Some authors have indeed suggested that "silent stroke" is an 
oxymoron, for stroke is by definition a symptomatic event, and have instead 
offered "silent infarction" as a better term.15 Either way, the important point 
is that an entity exists, variously designated silent stroke, silent cerebral 
ischemia, or silent or asymptomatic cerebral infarction, which refers to 
computerized tomographic (CT) evidence of cerebral infarction (hypodense 
lesions, or lucencies) without a prior history of stroke.!6 As this 
phenomenon has entered the literature relatively recently, limited 
information about this important finding exists, and in fact, the prevalence in 
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the general population has not to date been documented. Nevertheless, 
silent cerebral infarction among certain subgroups has been examined. The 
following section will discuss the information about silent stroke in patients 
with clinically evident stroke, with a history of TIA, and with carotid disease 
(Table 4). Following this analysis, the important and still-emerging 
relationship between silent cerebral infarction and atrial fibrillation will be 
addressed (Table 5). 
2. Silent Cerebral Infarction in Patients with Symptomatic Stroke or 
TIA 
The prevalence of silent stroke in patients who present with 
symptomatic stroke has been investigated in two studies. One of these was 
conducted by the Framingham investigators,^6 and the other utilized the 
National Institute of Neurological and Communicative Disorders and Stroke 
(NINCDS) data bank.l'7 The Framingham study focused on 124 patients with 
initial neurologic events who underwent CT scanning at the time of the 
initial event. This study found that 13 out of the 124 patients, or 10.5 percent, 
had evidence of silent infarction. Fifty percent of the lesions in these patients 
represented lacunar strokes in the basal ganglia and internal capsule areas, 
while the other fifty percent were small cortical infarcts. The authors 
postulated that these infarcts were silent either due to their size or their 
location, or because the defect produced was not noticed by the patient (e.g., 
quadrantanopia). Among patients with silent infarction, hypertension (76.9 
percent of these patients), smoking (53.8 percent), and atrial fibrillation (23.1 
percent) were found to be risk factors, but only glucose intolerance was 
statistically more common in the silent stroke group relative to the 




The interrogation of the NINCDS data revealed the prevalence of 
silent stroke to be 11 percent (135 out of 1203 patients),! ^ which is almost 
identical to that obtained from the Framingham data. Of note, however, 
"silent stroke" in this study consisted both of asymptomatic (74.9 percent) and 
unreported but clinically evident lesions (25.1 percent) unrelated to the initial 
reported (presenting) stroke event, thus expanding the Framingham 
definition. However, the majority of patients (74.9 percent) fit the 
Framingham definition. As in Framingham, two geographic patterns were 
identified: one of small, deep lesions, and the other consisting of large, 
superficial lesions. This study concluded, in accord with Framingham, that 
the silence of the infarcts was due to their small size and location in the depth 
of the hemisphere (while noting that the unreported but clinically evident 
group often had visual defects, e.g. hemianopia or more commonly 
quadrantanopia which went unnoticed). There was no difference in the 
incidences of hypertension, prior myocardial infarction, atrial fibrillation, 
diabetes mellitus, or prior TIA in patients with silent infarctions relative to 
the remainder of the stroke data bank patients. However, age was identified 
as a positive risk factor for silent infarction. Thus it seems from these two 
studies that among patients who develop symptomatic stroke which brings 
them to the attention of a physician and thence to the CT scanner, silent 
cerebral infarction is not an uncommon finding. The risk factors which 
isolate patients within this group as more likely to have evidence of silent 
infarction have not been clearly defined, with only age and glucose 
intolerance as possible independent variables. At issue, however, are risk 
factors which distinguish among stroke patients. Thus hypertension, atrial 
fibrillation and coronary disease are not ruled out as independent risk factors 
for silent infarction. Indeed, a recent study by a Japanese investigative team 

has suggested that in addition to age, hypertension is an independent risk 
factor for silent infarction in patients with coronary heart disease.! 9 
Another study of silent infarction analyzed data generated by the Dutch 
TIA study. 19 The cohort in this study consisted of 2329 patients with a history 
of TLA or minor ischemic stroke. Among this group, 13 percent had evidence 
of silent cerebral infarction; 79 percent of these lesions were lacunar, 14 
percent were cortical, and 7 percent were located in the border zone. Age 
greater than 65, hypertension, and current cigarette smoking were identified 
as risk factors for silent stroke in these patients, consistent with the 
Framingham and NINCDS results. 16-17 Importantly, atrial fibrillation was 
an exclusion criterion for the Dutch trial. In addition, both this study and the 
NINCDS analysis found that silent stroke was more likely to be accompanied 
by symptomatic lacunar as opposed to symptomatic cortical infarct, when a 
patient had both silent and symptomatic infarction. 17,19 Finally, the 
investigators in this study hypothesized that "because only the sites of silent 
stroke infarcts differed slightly from those of symptomatic infarcts, and the 
frequency of vascular risk factors was similar to that of symptomatic infarcts, 
silent stroke may have the same bearing on future risk as known prior 
stroke."!'7 Of note, this was only an hypothesis, not a demonstrated 
conclusion of the study. 
3. Silent Cerebral Infarction and Carotid Disease 
Next, a number of investigators have examined the link between 
carotid disease and silent infarction. In short, these studies show the 
relationship to be unresolved. In one study, 96 patients admitted for carotid 
thromboendarterectomy underwent preoperative CT scanning, which 
revealed 17 patients, or 18 percent, to have silent infarctions, predominantly 
lacunar.20 The incidence of hemodynamically significant carotid stenosis (14 

out of 17) and ulcerated bifurcation plaque (7 out of 17) was not statistically 
different from that in patients without silent infarction; in fact, the 
ulcerations occurred on the side of the infarction in less than half of the cases. 
In addition, 5 of these 17 patients had transient ischemic attacks appropriate to 
the location of the infarction. These investigators concluded that the 
processes of infarction and carotid disease are most likely parallel processes 
which share common risk factors, in particular, smoking and hypertension, 
which were also found to be risk factors in the above studies. 16-19 
To the contrary, however, a study examining the relationship between 
carotid stenosis and silent cerebral infarction concluded that the more severe 
the carotid stenosis, the higher the incidence of cerebral infarction ipsilateral 
to the stenosis. 15 in this study, 137 out of 381 patients, or 39 percent, had 
"positive CT scans." The problem with this study, however, is its failure to 
identify whether patients with TIAs (266 out of 381 patients) had infarcts in 
the distribution corresponding to the TIA symptoms, for indeed it has been 
noted that even with TIAs of no more than a few minutes' duration, an 
appropriate infarct (cerebral infarction with transient signs) can be found on 
CT scan.21 Thus the lesions in these patients may represent TIAs as opposed 
to silent infarctions. Of the 115 patients without a history of TIA, only 19 
percent had positive CT scans. Again, however, a problem arises in the 
interpretation of the data, namely the failure to define the extent and 
laterality of the stenoses in this 19 percent. Thus, while this study may 
suggest a causal link between carotid stenosis and cerebral infarction, further 
clarification is required before meaningful conclusions can be reached. 

D. Silent Cerebral Infarction and Atrial Fibrillation (Table 5) 
The above studies suggest that the traditional stroke-related risk factors 
of age, hypertension, cigarette smoking, and diabetes may be independently 
related to the development of silent cerebral infarction, while the 
relationship of carotid disease to silent infarction requires further study. 
What then of the final group of patients in whom silent infarction has been 
identified, namely those patients with atrial fibrillation? 
1. Patients with a History of Symptomatic Stroke or TIA 
The literature addressing the relationship of atrial fibrillation and 
silent cerebral infarction is sparse, with only five studies specifically designed 
to examine this issue. Kempster, et. al. compared 58 patients in chronic atrial 
fibrillation with 168 patients in sinus rhythm; all patients from both groups 
presented with a clinically evident neurologic event.22 These investigators 
discovered a statistically significant difference in the prevalence of silent 
cerebral infarction between the two groups, namely 13 percent of patients 
with atrial fibrillation versus 4 percent of the patients in sinus rhythm 
(p<0.05). All of the infarctions among the atrial fibrillation patients were 
peripherally located, while 3 out of the 7 lucencies among patients in sinus 
rhythm represented deep lacunar lesions. The importance of this territorial 
distribution relates to the fact that cardiac emboli are characteristically 
associated with cortical or large subcortical strokes, while lacunar strokes are 
only rarely thought to be embolic in origin.20,22-23 Thus the peripheral 
location of the infarctions in the atrial fibrillation group is consistent with an 
embolic source. The higher prevalence of silent cerebral infarction in stroke 
and TIA patients with atrial fibrillation corresponds to the results obtained by 
Weisberg, who found silent cerebral infarctions in 18 percent of 35 post-stroke 

CT scans of patients in atrial fibrillation.24 Finally, a Japanese investigative 
team published an abstract of a case-control trial similar to that of Guidotti, 
and found the incidence of silent infarction to be 58 percent among chronic 
atrial fibrillators, 38 percent in patients with paroxysmal atrial fibrillation, and 
13 percent among patients in sinus rhythm.27 However, information crucial 
to evaluating this data, namely sample size and statistical significance, were 
not included in the abstract. 
2. Patients without Symptomatic Stroke or TIA 
Three studies have examined the prevalence of silent cerebral 
infarction in atrial fibrillation patients without any documented history of 
stroke or TIA. Petersen, et. al. compared 29 patients with chronic atrial 
fibrillation to 29 age- and sex-matched controls.25 This study revealed that 48 
percent of the chronic atrial fibrillators versus 28 percent of the controls had 
evidence of silent infarction on CT scan (a nonstatistically significant 
difference). However, there was a statistically significant difference in the 
number of lesions between the two groups-- 39 in the atrial fibrillation group 
versus 16 in the control group. Of note, these lesions were "mainly" cortical, 
which as noted above, is a finding consistent with an embolic source. In 
another, similar study, Guidotti, et. al. compared 72 patients with chronic 
atrial fibrillation against 72 age- and sex-matched controls, and found that 44 
percent of the atrial fibrillation patients, versus 11 percent of the control 
patients, had evidence of silent infarction on CT scan— a statistically 
significant difference (p<0.05).26 Of the lesions in the atrial fibrillation group, 
66 percent were subcortical, while 33 percent were cortical, as compared with 
100 percent subcortical lesions in the control group. Importantly, this study 

revealed a higher (not statistically significant) prevalence of hypertension and 
diabetes in the atrial fibrillation group. 
Feinberg, et. al. 23 used the SPAF^ data bank, excluding patients with a 
history of stroke or TIA, and determined the prevalence of silent infarctions 
among 141 patients with nonvalvular atrial fibrillation; both chronic and 
intermittent fibrillators were included. Of these 141 patients, 36 (26 percent) 
had CT evidence of silent infarction; 81 percent of these 36 patients had small 
deep infarcts less than one centimeter, while 36 percent had cortical or large 
deep infarctions. Additionally, 33 percent of CT scans had greater than one 
hypodense lesion. To define prevalence, this group investigated risk factors, 
and noted that age and left atrial (LA) diameter significantly influenced the 
prevalence of silent infarction. In particular, in patients with LA diameter 
greater than 5.0 cm and age greater than 65, the prevalence of silent infarction 
was 52 percent; in patients with either one but not both of these risk factors, 
the prevalence was 24 percent, while in patients with neither risk factor, the 
prevalence was 11 percent. The study did not, however, find hypertension, 
diabetes, the duration of the arrhythmia, congestive heart failure, a history of 
myocardial infarction, or left ventricular dysfunction statistically more 
common among the atrial fibrillation patients with silent infarction, 
although the investigators noted that their small sample size may have 
limited their ability to detect an association. The prevalence of silent 
infarction among patients in this study with chronic atrial fibrillation was 34 
percent against 22 percent in patients with intermittent atrial fibrillation. 
The Feinberg study thus identified left atrial diameter and age as 
positive risk factors for silent infarction among patients with atrial 
fibrillation. In light of this finding, the investigators proposed that because 
the prevalence of the major stroke risk factors of hypertension and diabetes 

were similar in patients with and without silent infarction, cerebrovascular 
disease may not fully account for the occurrence of these infarctions. Rather, 
the positive correlation with left atrial diameter, combined with the fact that 
chronic atrial fibrillation patients who generally have a greater left atrial 
diameter than patients with intermittent atrial fibrillation have a greater 
incidence of silent infarction than these patients, supports the idea that atrial 
thrombi are responsible for these silent infarctions. The investigators did 
acknowledge, however, that the risk factor of left atrial size by itself, while 
perhaps causally related to the pathophysiology of these infarctions, may also 
be simply a marker of those at risk. 
3. Limitations of the Five Studies of Silent Infarction in Patients with 
Atrial Fibrillation 
The conclusions which may be drawn from the above studies about the 
relationship between atrial fibrillation and silent infarction are limited by 
certain factors inherent to their design. One problem addressed above is the 
difficulty of accurately characterizing lesions as silent in the absence of regular 
neurologic examinations. The classification of lesions as silent goes to the 
heart of these studies, and thus any inaccuracy in this classification necessarily 
renders the interpretation of these studies and comparisons among them 
problematic. This classification difficulty arises from another feature of the 
design of these studies, namely that they were all retrospective. What is 
needed then is a prospective study which follows patients with regular 
neurologic histories and physical examinations, and neuroradiologic imaging 
at defined intervals. In this way, lesions identified on CT scans may be 
definitively correlated with the neurologic signs and symptoms developed 
among patients in the study, with the result being more accurate delineation 
of lesions as silent or symptomatic, and incidence data which more closely 

represents the true frequency of silent infarction in patients with atrial 
fibrillation. Finally, the sample size in all of the above studies is relatively 
small; although statistically significant results of one form or another were 
obtained in most of these studies, a larger patient population would yield 
more confident data on the important finding of silent infarction in the 
subgroup of patients with atrial fibrillation. 
E. Conclusion 
Studies to date have thus demonstrated that silent cerebral infarction is 
not an uncommon finding in patients with either chronic nonvalvular atrial 
fibrillation or a history of a clinically evident neurologic event. In addition, 
the traditional stroke-related risk factors of age, hypertension, smoking, and 
diabetes may be positively and perhaps independently related to the 
development of silent infarction, although this remains unsettled. A 
number of important issues regarding silent cerebral infarction are as yet 
unresolved. In particular, the prevalence of silent infarction among the 
population at large is unknown. The mechanism of silent infarction, while 
traditionally thought to be secondary to thromboemboli (a notion which is 
perhaps supported by the territorial distribution of infarctions as discussed 
above), has yet to be conclusively demonstrated. Moreover, the very 
important question of the impact of silent cerebral infarction on the risk of 
later clinically significant events, and perhaps on the development of such 
conditions as multi-infarct dementia, remains uncovered. And finally, the 
effect of warfarin prophylaxis on the incidence of silent infarction has not 
been examined. If indeed silent infarction proves to be a significant risk factor 
for later symptomatic disease, an argument could be made for early 

anticoagulation. Thus the delineation of subgroups at risk will be a major 
advance toward the goal of protecting patients from both silent infarction and 
its serious sequelae. 
III. STUDY QUESTION 
What is the prevalence of silent cerebral infarction among patients at 
entry into the Stroke Prevention in Nonrheumatic Atrial Fibrillation Study 
(SPINAF), what risk factors are associated with silent infarction, what is the 
location of these infarctions, what is the incidence of silent infarction during 
the course of the study, what if any is the relationship of silent infarction to 
warfarin therapy and to the development of symptomatic stroke, and what 
are the clinical implications of these findings? 
IV. METHODS* 
A. Design of the SPINAF study12 
Stroke Prevention in Nonrheumatic Atrial Fibrillation (SPINAF), a 
Veterans Affairs Cooperative Study, was conducted in 16 Department of 
Veterans Affairs Medical Centers. Male veterans of any age, without 
echocardiographic evidence of rheumatic heart disease, who had atrial 
fibrillation documented by two electrocardiograms at least four weeks apart 
were considered for inclusion in the study. Baseline prothrombin times had 
to be within normal range. Aspirin and nonsteroidals were withdrawn if 
* As indicated, the data analyzed herein were acquired during the SPINAF 
study, which was terminated on March 1, 1991. 

both physician and patient agreed. For Arm I of the study, only patients 
without clinical evidence of stroke were included. Exclusion criteria are 
summarized in Table 6. 
Each center had both a blinded and an unblinded team. Patients were 
randomly assigned to receive warfarin or placebo. The goal of warfarin 
therapy was the maintenance of a prothrombin-time ratio of 1.2 to 1.5. All 
patients were followed for three years or until the termination of the study. 
Patients who had a cerebral event were followed for survival. 
The primary endpoint of the study was clinically evident cerebral 
infarction, defined as a new neurologic deficit not attributable to dysfunction 
of a single cranial nerve, the spinal cord, or the peripheral nervous system, 
with persistence of the deficit or some portion thereof for longer than 12 
hours and an absence of evidence of intracerebral hemorrhage or tumor on 
the first cranial CT scan obtained after the onset of the deficit. The secondary 
endpoints were cerebral hemorrhage and death. 
B. CT Scan Acquisition and Analysis 
Non-contrast CT scans were obtained from each patient at entry and 
upon leaving the study. Scans were also obtained, as indicated above, in 
patients who suffered clinical strokes. Copies of all scans were sent to the 
study chairman's office at the West Haven, Connecticut, Veterans Affairs 
Medical Center, where they were evaluated centrally by a committee 
consisting of six neurologists and neuroradiologists. Each scan was read by 
two members of the committee, and their consensus findings were entered 
into a data base. The location, size, and vascular territory of all hemorrhagic 
or lucent lesions were archived. The data base was modeled after published 

NINCDS forms,28 and the territories were based on previously published 
templates.29 if consensus was not reached between the two examiners, the 
CT scan was arbitrated by the entire six-member committee. 
Lucencies of 4.2 cm (corresponding to a diameter of 2.0 cm if they were 
perfect spheres) or greater were considered to be large infarctions.2b This 
choice was based on the commonly accepted upper limit of diameter for 
lacunar strokes as formulated by C. M. Fisher.30 For study purposes, 
presumed strokes were divided into: a. large or small; b. subcortical (deep), 
cortical (superficial), or spanning both areas; c. anterior circulation, posterior 
circulation, or watershed. The size of the stroke was estimated by recording 
the maximal dimensions in millimeters in the x and y axes, then multiplying 
the area thus obtained by the number of 10 mm slices (N) on which the 
lucency appeared. The spherical volume was calculated by the formula 
V(cm3) = (x) (y) (N) (10) (pi) / (6) (1000), 
which is based on the formula for the volume of a spheroid of principal 
diameters a, b, and c: 
V(cm3) = (a/2) (b/2) (c/2) (4/3) (pi). 
C. Other Tests 
Bilateral carotid duplex studies were performed on a subset of patients 
(323) entering the SPINAF trial. In addition, transthoracic echocardiography 
as well as equilibrium radionuclide angiography (ERNA) were carried out on 
all patients. 
D. Data Analysis 
The data were analyzed at the Cooperative Studies Program 
Coordinating Center in Palo Alto, California. All analyses were performed on 

an intention-to-treat basis. Baseline characteristics of patients with silent 
infarctions versus patients without silent infarctions were compared using 
the Student's t-test for continuous variables and Chi-square for 
noncontinuous variables. Ninety-five percent confidence intervals were 
calculated for the relative risk of silent infarction using the Taylor series 
approximation for the variance of the risk ratio.31 The Mantel-Haenszel 
statistic^ was used to assess the effect of silent cerebral infarction at entry on 
the occurrence of symptomatic stroke, combined across placebo and warfarin 
groups. Scans that were obtained outside of the acceptable windows of ninety 
days before and thirty days after entry, or thirty days before and ninety days 
after termination (the "window criteria") were excluded from analysis. 
V. RESULTS 
A. Prevalence of Silent Cerebral Infarction 
525 patients participated in Arm I of the SPINAF study. Of these, 6 
were missing their initial scans, and 3 had scans which did not meet the 
window criteria (see METHODS, Data (section III.D)). Thus, the prevalence of 
silent infarctions was based on 516 initial CT scans. Of these 516 scans, 77, or 
14.9 percent, had evidence of silent cerebral infarction. 60 of these scans had 1 
lesion, 12 scans had 2 lesions, 3 scans had 3 lesions, and 2 scans had 4 lesions. 
Thus of the 77 positive scans, 60 (78 percent) had a single lesion, while 17 (22 
percent) had multiple lesions, producing a total of 101 lesions. 

B. Location and Size Distribution among the 77 Positive Scans (Table 7) 
Of the 60 CT scans with single lesions, 30 (50 percent) had lesions which 
were small and subcortical, 5 (8 percent) had lesions which were large and 
subcortical, 3 (5 percent) had lesions which were small and cortical, and one 
scan had a large, cortical lesion. Twenty lesions in this group (6 small and 14 
large) spanned both the cortical and subcortical regions. 
Among the 17 CT scans with multiple lesions, the majority (10/17) had 
lesions which were small and subcortical or small and spanned both the 
cortical and subcortical regions. The remaining lesions were a combination of 
small, large, cortical, and subcortical. 
C. Location and Size Distribution of the 101 Silent Infarctions 
Of the 100 lesions which had specified locations (one location was 
missing), 59 were subcortical, 10 were cortical, and 31 spanned both cortical 
and subcortical areas. Seventy-three (72 percent) were small, and 28 (28 
percent) were large. 
D. Vascular Distribution among the 77 Positive Scans (Table 8) 
Of the 60 CT scans showing single lesions, 44 (73 percent) had lesions in 
the distribution of the middle cerebral artery, 7 (12 percent) had lesions in the 
distribution of the posterior cerebral artery, 5 (8 percent) had lesions in the 
region of the cerebral watershed (spanning both the anterior and posterior 
circulations), and the remaining 4 (7 percent) were distributed across the 
cerebellar area of the brain. 
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In the 17 scans with 41 multiple lesions, 26 (63 percent) of the lesions 
were in the distribution of the middle cerebral artery, 4 (10 percent) of the 
lesions were in the distribution of the posterior cerebral artery, 9 (22 percent) 
of the lesions were in the region of the cerebral watershed, and 2 (5 percent) of 
the lesions were in the distribution of the anterior cerebral artery. 
E. Risk Factors for Silent Cerebral Infarction among Patients at Entry with 
Evidence of Silent Infarction (Table 9) 
Table 9 presents a univariate comparison of the baseline characteristics 
for patients with and without evidence of silent cerebral infarction upon 
entry into the SPINAF study. These data suggest that age (p=0.011), a history 
of hypertension (p=0.003), and active angina (p=0.012) were predictive of 
silent infarction. In addition, the mean systolic blood pressure of those 
patients who had a silent stroke prior to entry was significantly higher than 
that of patients who did not have evidence of silent infarction (p<0.0001). Of 
note, left atrial diameter, a history of myocardial infarction, left ventricular 
ejection fraction, cigarette smoking, a history of congestive heart failure, 
mitral annular calcification, mitral valve prolapse, a history of diabetes, and 
the documented duration of atrial fibrillation did not significantly correlate 
with silent infarction. 
Of the 516 patients with analyzable scans at entry, 323 had bilateral 
carotid Doppler studies (Table 9). Of the 287 patients with normal carotid 
studies, 39 (13.6 percent) had evidence of silent infarction. Of the 24 patients 
with abnormal but subcritical studies, 3 (12.5 percent) had evidence of silent 
infarction. Finally, of the 12 patients with critical stenosis (greater than 75 
percent occlusion), 3 (25 percent) had evidence of silent infarction. However, 
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while there was a trend towards increased prevalence of silent infarctions in 
patients with critical carotid stenosis, it was not statistically significant. 
F. Incidence of Silent Cerebral Infarction During the Course of the Study 
(Tables 10); the Effect of Warfarin 
Of the 525 patients randomized in SPINAF, 307 had both an initial scan 
taken at the beginning of the study and a final scan at termination to detect 
silent cerebral infarction. Final scans were not available on patients who died 
(37), who were terminated at their request or for administrative reasons (43), 
or were lost to follow-up or otherwise could not be contacted (19). Final scans 
on patients who suffered a clinical stroke (23) or hemorrhage (1) were not 
performed. Scans on these patients were performed only at the time of the 
event. Sixty-nine patients had missing scans and 26 patients had scans that 
did not meet the window criteria. 
Of the 307 patients who had scans at entry and termination, 40 had 
scans that were abnormal at entry. The incidence rate of silent cerebral 
infarction among the 267 patients who had normal entry scans was 1.77 
percent/year in the warfarin group, and 0.77 percent/year in the placebo 
group. The relative risk of silent infarction for warfarin patients was more 
than twice that for placebo patients, but the 95 percent confidence interval was 
very wide and overlapped 1.0. 

G. Silent Cerebral Infarction as a Risk Factor for the Development of 
Symptomatic Stroke (Table 11) 
During the course of the SPINAF study, 23 patients (19 in the placebo 
group and 4 in the warfarin group) presented with symptomatic stroke. Of 
the 43 patients in the placebo group with evidence of silent infarction at entry, 
5 (11.6 percent) developed symptomatic stroke; of the 217 placebo-treated 
patients without evidence of silent infarction at entry, 14 (6.5 percent) 
developed symptomatic stroke. Of the 34 patients in the warfarin group with 
evidence of silent infarction at entry, 2 (5.9 percent) developed symptomatic 
stroke; of the 222 warfarin-treated patients without evidence of silent 
infarction at entry, 2 (0.9 percent) developed symptomatic stroke. Combining 
the placebo and warfarin groups using the Mantel-Haenszel procedure 
resulted in a p value of 0.051. This suggests that patients with evidence of 
silent cerebral infarction at entry to the SPINAF study may have been more 
likely to develop symptomatic stroke than patients without evidence of silent 
infarction. 
VI. DISCUSSION 
Major Findings of the Study 
The prevalence of silent infarction among patients in the SPINAF 
study was 14.9 percent. The majority of the lesions were small and 
subcortical, involving the anterior circulation, primarily in the distribution of 
the middle cerebral artery. Age, a history of hypertension, active angina, and 
mean systolic blood pressure were predictive of silent infarction. Silent 
infarction, in turn, was suggestive of the development of symptomatic stroke. 
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Warfarin did not appear to influence the development of silent infarction, 
although the number of events occurring during the course of the study was 
very small, resulting in wide 95 percent confidence limits on the relative risk 
of warfarin compared to placebo. 
Prevalence 
The prevalence of silent infarction in this study is similar to that found 
by Kempster, but is somewhat lower than in the other studies of atrial 
fibrillation patients (Table 5). The 14.9 percent prevalence is, however, in the 
same range as that documented among stroke, TIA, and preoperative carotid 
endarterectomy patients (Table 4). The important point which emerges, even 
when the lowest documented prevalence is considered, is that silent 
infarction is not an uncommon finding among subgroups of patients with a 
history of stroke, TIA, carotid disease, or atrial fibrillation. 
Risk Factors 
The predictive factors of age and hypertension in this study are in 
accord with those found in the Dutch TIA study. 19 The Feinberg23 and 
NINCDS^ studies identified age but not hypertension as positive risk factors. 
The Feinberg study also found left atrial diameter to be a risk factor for silent 
stroke, in contradistinction to the SPINAF results. Only the SPINAF study 
identified active angina as a positive risk factor. 
Location 
Fifty-nine percent of the lesions in the SPINAF study were subcortical; 
72 percent were small and 28 percent were large. A higher percentage of 
subcortical lesions was also identified in the Dutch TIA^, Guidotti^6/ 
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Feinberg23/ and carotid endarterectomy^ studies. The Kempster^ 
Petersen^, and Framingham^ studies did not share this finding. As noted 
earlier, strokes resulting from cardiac emboli are characteristically associated 
with cortical or large subcortical lesions, while lacunar strokes are rarely 
thought to be embolic in origin.20,22-23 Nevertheless, the Feinberg study, 
looking towards its identified risk factor of left atrial diameter, concluded that 
atrial thrombi were responsible for the silent infarctions found in that study. 
Importantly, as noted above, these investigators did not find hypertension to 
be a positive risk factor. 
Proposed Mechanism of Silent Infarction; The Effect of Warfarin 
The SPINAF data seem to support a different mechanism for silent 
stroke, namely hypertensive small vessel disease. Consistent with this 
mechanism are the high percentage of lacunar strokes documented in this 
study (and in the Dutch TLA^ carotid endarterectomy^O, Guidotti^ and 
indeed Feinberg23 studies), as well as the very significant association of silent 
infarction with a history of hypertension and systolic blood pressure. It 
would indeed be difficult to account for the large number of subcortical 
lesions if atrial thrombi were thought to be the main culprit. Importantly, 
although the data were not statistically significant, warfarin therapy did not 
influence the development of symptomatic stroke during the course of the 
SPINAF study. This of course is the expected finding if hypertensive small 




The low incidence of silent infarction during this study when 
compared to the prevalence of silent infarction at entry may be due to the 
detailed neurological histories at entry and the intensive neurological follow¬ 
up during the study. Indeed, many of the lesions identified as silent 
infarctions in other studies may have been clinically evident but not 
identified as such by the health care team. In addition, there is some 
definitional ambiguity in the literature as to what exactly constitutes a silent 
infarction; for example, in the Framingham study! 6, "silent strokes" 
included only lesions unrelated to the presenting event and with no 
documented clinical presentation, while in the NINCDS study!-7, both 
asymptomatic lesions unrelated to the presenting event and symptomatic 
unreported events unrelated to the initial presenting event but discovered on 
physical examination at the time of the initial event were included. Thus 
there is difficulty in classifying an infarction as silent in the absence of regular 
intensive neurologic examination. The corollary to this observation is that 
the incidence of silent infarction observed in this study may be a more 
accurate reflection of the true frequency among the population of patients 
with atrial fibrillation. 
Relationship of Silent Infarction to the Development of Symptomatic Stroke: 
Clinical Implications 
Another important result of this study is the suggestion that silent 
infarction is a marker for the development of symptomatic stroke. If indeed 
hypertensive small vessel disease is the main mechanism of silent infarction, 
then perhaps silent stroke is truly that— in other words, subclinical disease 
which shares the same etiology and mechanism as symptomatic stroke in 
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most patients. This being the case, then, silent stroke and symptomatic stroke 
among patients with atrial fibrillation (in whom left atrial thrombi are 
thought to account for the increased risk of symptomatic stroke) may have 
distinct etiologies, with hypertensive small vessel disease responsible for the 
majority of silent infarctions, and left atrial thrombi the mechanism of the 
majority of symptomatic strokes. From a therapeutic-preventative 
standpoint, then, both warfarin and antihypertensive therapy would play 
significant roles in the prevention of symptomatic stroke in patients with 
atrial fibrillation: Warfarin to prevent the formation of left atrial thrombi, 
and antihypertensive therapy to forestall the development of small vessel 
disease, which presumably causes silent infarction as well as its more serious 
relative, symptomatic stroke. The next step to confirm this hypothesis would 
thus be an examination of the effect of antihypertensive therapy on the 




Table 1. Noncardiac Causes Of Ischemic Cerebrovascular 
Disease 
(adapted from Harrison's Principles of Internal Medicine1) 
Atherosclerosis 
Arteritis (e.g. temporal, granulomatous, polyarteritis, Wegener’s) 
Dissections (e.g. carotid, vertebral) 
Hematologic disorders (e.g. polycythemia, sickle cell disease, I I P) 
Cerebral mass effect compressing intracranial arteries (e.g. tentorial herniation of 
posterior cerebral artery) 
Cerebral vasospasm 
Reversible cerebral vasoconstriction (e.g. migraine, trauma, eclampsia) 
Atherothrombotic arterial source (e.g. at bifurcation of common carotid artery) 
Miscellaneous (e.g. fibromuscular dysplasia, Binswanger's disease) 
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Table 2. Causes of Cardiac Sources of Systemic Embolization 
(from Cardiovascular Pharmacology and Therapeutics, Chapter 
373) 
Left Ventricle 
Acute anterior transmural myocardial infarction 
Acute inferior transmural myocardial infarction with apical involvement 




Endocarditis, infective and noninfective 
Prosthetic valve dysfunction 
Mitral prolapse 
Rheumatic heart disease 
Left Atrium 
Atrial fibrillation 
Left atrial tumors (myxoma) 
Atrial septal aneurysm 





Table 3. Conditions Associated with Atrial Fibrillation 





Congenital heart disease 
Hypertension 




























# PATIENTS %(#) SILENT 
INFARCTIONS COMMENTS 
Framingham 16 Stroke 124 10.5(13)* 1. 8 lacunar, 7 cortical; 
2. glucose intolerance 
found more frequently 
(p<0.05) in SCI 
patients. 
NINCDS17 Stroke 1203 11(135)* 1. lacunar v. cortical 
not documented; 
2. age positively 




TIA 2329 13(314)* 1. 79% lacunar, 14% 
cortical, 7% border 
zone; 
2. age > 65, 
hypertension and current 
cigarette smoking 






or TIA with or 
without carotid 
stenosis 
381 39(137) 1. 39% lacunar, 61% 
cortical cm- superficial 
subcortical; 
2. Classification of 
lesions as silent 
somewhat suspect given 
failure to correlate 
location of lesions with 
symptomatic 




Pre-operative 96 18(17)* 1. 10 lacunar, 5 
cortical, 1 cortical/ 
lacunar, 1 cerebellar. 
*Silent infarction = hypodense lesion on CT scan unrelated to presenting event and with no 
documented clinical presentation 
tSilent infarction = both asymptomatic lesions unrelated to presenting event (74.9% of patients) and 
sympotmatic unreported (undetected) events unrelated to initial presenting event 




TABLE 5. PREVALENCE OF SILENT CEREBRAL INFARCTION (SCI)* 








% OF PATIENTS W/ SCI 
AF CONTROL 
PATIENTS COMMENTS 
Kemps ter22 + 13 4 1. statistically significant difference; 
2. only chronic AF patients included; 
3. all lesions in AF patients “peripherally 
located.” 
Sasaki27 + 58, 38 (see 
comment 2) 
13 1. No data included in Abstract regarding 
statistical significance; 
2. Percents represent chronic and 
paroxysmal atrial fibrillators, respectively; 
3. No data as to location of lesions included 
in the Abstract; 
4. As neither sample size nor statistical 
analysis were included in the Abstract, the 
significance of these results is unclear. 
Petersen25 48 28 1. difference in prevalence not statistically 
significant, but statistically significant 
difference in the number of lesions (39 v. 
16); 
2. only chronic AF patients included; 
3. all lesions "mainly" cortical. 
Guidotti26 44 11 1. statistically significant difference; 
2. only chronic AF patients included; 
3. among AF patients, 66% of lesions were 
subcortical and 33% cortical, versus 100% 
subcortical in the control group. 
Feinberg23 26 1. study of 141 patients from SPAF^study; 
2. left atrial diameter > 5.0cm and age > 65 
positively associated with incidence of SCI; 
3. both chronic and intermittent AF 
patients included; 
4. 81% of patients with SCI had small deep 
infarcts, 36% had cortical or large deep 
infarcts; 
5. 33% of scans had multiple lesions. 
♦Silent infarction = hypodense lesion on CT scan unrelated to presenting event and with 
no documented clinical presentation 
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Table 6. Exclusion of Patients with No History of Cerebral 
Infarction Who were Screened for the Study12* 
category no. 
Patients screened 7982 
Patients excluded 7444 
Intermittent atrial fibrillation 1732 
Definite indication for anticoagulation or antiplatelet agents 901 
Prosthetic heart valve 495 
Mitral stenosis 294 
Active thromboembolic disease 194 
Coronary artery bypass surgery 12 
Intracardiac thrombus 4 
Myocardial infarction within 1 month 3 
Contraindication to anticoagulation 3206 
Chronic alcoholism or psychological, social or general condition rendering the patient 
unsuitable for anticoagulation 2304 
Coexisting medical disorder 996 
Prothrombin time outside normal range 278 
Hemostasis disorder 210 
Documented peptic ulcer disease within 2 years1-, known as esophageal varices, or 
history of intracranial hemorrhage 57 
History of gastointestinal hemorrhage within 2 years1- 32 
Planned surgery or invasive procedure1- 23 
Laboratory abnormalities^; hematocrit < 32%; platelet count < 100,000/mm; 
serum aspartate aminotransferase, serum alanine aminotransferase, or alkaline 
phosphatase 2 times upper limit of normal; guaiac-positive stool; or > 5 red 
cells per high-power field in urine 17 
Uncontrolled hypertension (> 180/105 mm Hg)1- 6 
Bacterial endocarditis 1 
Atrial tumor 1 
Inappropriate for the study (administrative criteria) 1605 
Unable or unwilling to complete follow-up 698 
Received anticoagulation within past 6 months for more than 1 continuous month 477 
Use of aspirin or nonsteroidal antiinflammatory agent 468 
Echocardiogram uninterpretable 334 
Transient ischemic episodes within 5 years 195 
Previous cerebral infarction 31 
Hyperthyroidism 29 
Refused consent 23 
Cardioversion planned 16 
Unstable angina 5 
Patients randomly assigned to treatment 538 
Patients excluded after randomization 13 
Total patients included in analysis 525 
*The sura of the numbers within major categories may exceed the total because some 




Table 7. Location and Size of Silent Cerebral Infarctions* 
SIZE #(%) 
LOCATION SMALL LARGE MIXED* TOTAL 
CT Scans Subcortical 30(50) 5(8) — 35(58) 
with Single 
Lesions Cortical 3(5) 1(2) — 4(7) 
Border Zone* 6(10) 14(23) — 20(33) 
Unknown 1(2) — — 1(2) 
TOTAL 40(67) 20(33) — 60(100) 
CT Scans Subcortical 6(35) 1(6) 7(41) 
with 
Multiple Cortical 1(6) _ _ 1(6) 
Lesions 
Border Zone* 4(24) — 5(29) 9(53) 
TOTAL 11(65) -> 6(35) 17(100) 
*See METHODS (section IV) for a more detailed description of these classifications 
tMixed: Both small and large lesions present in CT scans with multiple lesions 
tBorder Zone: Area spanning both cortical and subcortical regions 
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Table 8. Vascular Distribution of Silent Cerebral Infarctions 
CT Scans with Single 
Lesions 
VASCULAR TERRITORY 




Anterior inferior cerebellar 
Posterior inferior cerebellar 
TOTAL 








Anterior cerebral 1(2) 
Middle cerebral artery 26(64) 
CT Scans with Posterior cerebral 4(10) 
Multiple Lesions 
Cerebral watershed 9(22) 




Table 9. Baseline Characteristics at Entry of Patients with 
Silent Cerebral Infarction (SCI) versus Those with 
Normal CT scans* 
NORMAL STATISTICALLY 
characteristic SCI (N=77) (N=439) pVALUE SIGNIFICANT 
(DENOTED X) 
Age (year) 69.4+6.9 67.017.2 0.011 X 
Duration of documented AF 
Left ventricular ejection 
7.7110.6 7.919.0 0.836 
fraction (%) 47.3113.3 47.9112.9 0.788 
Left atrial size (cm) 4.810.7 4.710.8 0.457 
Diastolic blood pressure 82.6110.0 80.9110.3 0.176 
Systolic blood pressure 141.7120.1 132.6118.5 0.000 X 
History of hypertension 
Cigarette smoking 
57(73%) 242(55%) 0.003 X 
current 
discontinued within 5 
8(10%) 75(17%) 0.138 
years'*' 10(14%) 42(12%) 0.521 
History of diabetes 16(21%) 75(17%) 0.469 
Angina 
History of myocardial 
25(32%) 88(20%) 0.012 X 
infarction 
History of congestive heart 
19(24%) 78(18%) 0.172 
failure 28(36%) 131(30%) 0.291 
No clinical heart disease* 1(1%) 15(3%) 0.487 
Mitral regurgitation13 0.763 
(0 - 1 +) 47(80%) 283(81%) 
(2+ or greater) 12(20%) 65(19%) 
Mitral annular calcification^ 17(22%) 68(16%) 0.170 
Mitral valve prolapse^ 2(3%) 13(3%) 1.000 
Carotid stenosis^ 0.615 
less than 50% 39(87%) 248(89%) 
50% or greater 6(13%) 30(11%) 
*AU values represent the mean ±1 standard deviation 
+Based on 69 patients with SCI and 358 without 
^Defined as normal left ventricular ejection fraction with no wall motion abnormality; no 
left ventricular hypertrophy, valvular disease, or mitral annular calcification; and no history 
of hypertension, myocardial infarction, angina, heart failure, or diabetes mellitus 
nBased on 59 patients with SCI and 348 without 
+Based on 77 patients with SCI and 432 without 
+Based on 77 patients with SCI and 433 without 
+Based on 45 patients with SCI and 278 without 

Table 10. Incidence of Silent Cerebral Infarction during the 









Patient-years 261.4 282.5 
Average follow-up (years) 2.1 2.0 — 
Silent cerebral infarction 2(0.77%)* 5(1.77%)* 2.29 
(0.52, 9.80j 
*Follow-up for patients whose scans were normal at entry into the study 
+Event rate (percent) per year 
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Table 11. Incidence of Symptomatic Stroke in Patients With and Without 
Silent Cerebral Infarction (SCI) at Entry 
PRESENCE OF SCI AT ENTRY 
TREATMENT Yes #(%) No #(%) Total 
Placebo Symptomatic stroke 5(11.6) 14(6.5) 19 
No symptomatic stroke 38(88.4) 203(93.5) 241 
TOTAL 43(100) 217(100) 260 
Warfarin Symptomatic stroke 2(5.9) 2(0.9) .4 
No symptomatic stroke 32(94.1) 220(99.1) 252 
TOTAL 34(100) 222(100) 256 
Mantel-Haenszel Chi-square p value 
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